Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

University of California San Diego researchers have identified a U-shaped association between high-density lipoprotein (HDL) ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Faricimab helped improve vision in previously untreated patients with neovascular age-related macular degeneration, according to a real-world study presented at Retina 2025. Ferhina S. Ali, MD, MPH, ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

In the last 20 years, there have been rapid advances in the treatment options for myopic ... it is possible that patients with myopic macular degeneration complicated by CNV may benefit from ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...